Publications by authors named "Jasgit Sachdev"

Claim this Profile
A
A phase Ib study of adavosertib, a selective Wee1 inhibitor, in patients with locally advanced or metastatic solid tumors.
Gerald S Falchook, Jasgit Sachdev, Esteban Rodrigo Imedio, Sanjeev Kumar, Ganesh M Mugundu

Invest New Drugs· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
DKK1 is a predictive biomarker for response to DKN-01: Results of a phase 2 basket study in women with recurrent endometrial carcinoma.
Rebecca Arend, Jhalak Dholakia, Cesar Castro, Ursula Matulonis, Erika Hamilton, Jasgit Sachdev

Gynecol Oncol· May 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pretherapy Ferumoxytol-enhanced MRI to Predict Response to Liposomal Irinotecan in Metastatic Breast Cancer.
Harshan Ravi, Andres M Arias-Lorza, James R Costello, Hyo Sook Han, Daniel K Jeong, Jasgit C Sachdev

Radiol Imaging Cancer· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Overcoming Taxane Resistance: Preclinical and Phase 1 Studies of Relacorilant, a Selective Glucocorticoid Receptor Modulator, with Nab-Paclitaxel in Solid Tumors.
Pamela N Munster, Andrew E Greenstein, Gini F Fleming, Erkut Borazanci, Manish R Sharma, Jasgit C Sachdev

Clin Cancer Res· August 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Multiple Gastrointestinal Symptoms Are Associated With Chemotherapy-Induced Nausea in Patients With Breast Cancer.
Komal P Singh, Kord M Kober, Brenda Ernst, Jasgit Sachdev, Melanie Brewer

Cancer Nurs· April 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
IOLite: phase 1b trial of doublet/triplet combinations of dostarlimab with niraparib, carboplatin-paclitaxel, with or without bevacizumab in patients with advanced cancer.
Timothy A Yap, Alberto Bessudo, Erika Hamilton, Jasgit Sachdev, Manish R Patel

J Immunother Cancer· March 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety, antitumor activity, and pharmacokinetics of dostarlimab, an anti-PD-1, in patients with advanced solid tumors: a dose-escalation phase 1 trial.
Amita Patnaik, Glen J Weiss, Drew W Rasco, Lisa Blaydorn, Amy Mirabella, Jasgit C Sachdev

Cancer Chemother Pharmacol· January 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
First-in-Human Study of PF-06647020 (Cofetuzumab Pelidotin), an Antibody-Drug Conjugate Targeting Protein Tyrosine Kinase 7, in Advanced Solid Tumors.
Michael L Maitland, Jasgit C Sachdev, Manish R Sharma, Victor Moreno, Valentina Boni

Clin Cancer Res· August 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I study of liposomal irinotecan in patients with metastatic breast cancer: findings from the expansion phase.
Jasgit C Sachdev, Pamela Munster, Donald W Northfelt, Hyo Sook Han, Cynthia Ma

Breast Cancer Res Treat· February 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of Capivasertib in Patients With an AKT1 E17K-Mutated Tumor: NCI-MATCH Subprotocol EAY131-Y Nonrandomized Trial.
Kevin Kalinsky, Fangxin Hong, Carolyn K McCourt, Jasgit C Sachdev, Edith P Mitchell

JAMA Oncol· February 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I Basket Study of Taselisib, an Isoform-Selective PI3K Inhibitor, in Patients with -Mutant Cancers.
Komal Jhaveri, Matthew T Chang, Dejan Juric, Cristina Saura, Valentina Gambardella, Jasgit C Sachdev

Clin Cancer Res· January 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A first-in-human, phase 1, dose-escalation study of ABBV-176, an antibody-drug conjugate targeting the prolactin receptor, in patients with advanced solid tumors.
Charlotte Lemech, Natasha Woodward, Nancy Chan, Joanne Mortimer, Louie Naumovski, Jasgit Sachdev

Invest New Drugs· December 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase 1 study of TTC-352 in patients with metastatic breast cancer progressing on endocrine and CDK4/6 inhibitor therapy.
Arkadiusz Z Dudek, Li C Liu, James H Fischer, Elizabeth L Wiley, Jasgit C Sachdev

Breast Cancer Res Treat· October 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I study of imalumab (BAX69), a fully human recombinant antioxidized macrophage migration inhibitory factor antibody in advanced solid tumours.
Devalingam Mahalingam, Manish R Patel, Jasgit C Sachdev, Lowell L Hart, Niels Halama

Br J Clin Pharmacol· September 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase 1 study of MRX34, a liposomal miR-34a mimic, in patients with advanced solid tumours.
David S Hong, Yoon-Koo Kang, Mitesh Borad, Jasgit Sachdev, Samuel Ejadi

Br J Cancer· May 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
First-in-Human Study of Mivebresib (ABBV-075), an Oral Pan-Inhibitor of Bromodomain and Extra Terminal Proteins, in Patients with Relapsed/Refractory Solid Tumors.
Sarina A Piha-Paul, Jasgit C Sachdev, Minal Barve, Patricia LoRusso, Russell Szmulewitz

Clin Cancer Res· November 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Single-Arm Phases 1 and 2 Trial of Niraparib in Combination With Pembrolizumab in Patients With Recurrent Platinum-Resistant Ovarian Carcinoma.
Panagiotis A Konstantinopoulos, Steven Waggoner, Gregory A Vidal, Monica Mita, John W Moroney, Jasgit C Sachdev

JAMA Oncol· August 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase 1, open-label, dose-escalation trial of oral TSR-011 in patients with advanced solid tumours and lymphomas.
Chia-Chi Lin, Hendrik-Tobias Arkenau, Sharon Lu, Jasgit Sachdev, Javier de Castro Carpeño

Br J Cancer· July 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Update on Precision Medicine in Breast Cancer.
Jasgit C Sachdev, Ana C Sandoval, Mohammad Jahanzeb

Cancer Treat Res· June 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and Antitumor Activity of Pembrolizumab in Patients with Estrogen Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer.
Hope S Rugo, Jean-Pierre Delord, Seock-Ah Im, Patrick A Ott, Sarina A Piha-Paul, Jasgit Sachdev

Clin Cancer Res· June 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and pharmacokinetics of veliparib extended-release in patients with advanced solid tumors: a phase I study.
Theresa L Werner, Jasgit Sachdev, Elizabeth M Swisher, Martin Gutierrez, Muaiad Kittaneh

Cancer Med· June 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correlation between Ferumoxytol Uptake in Tumor Lesions by MRI and Response to Nanoliposomal Irinotecan in Patients with Advanced Solid Tumors: A Pilot Study.
Ramesh K Ramanathan, Ronald L Korn, Natarajan Raghunand, Jasgit C Sachdev, Ronald G Newbold

Clin Cancer Res· July 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I, Dose-Escalation, Two-Part Trial of the PARP Inhibitor Talazoparib in Patients with Advanced Germline Mutations and Selected Sporadic Cancers.
Johann de Bono, Ramesh K Ramanathan, Lida Mina, Rashmi Chugh, John Glaspy, Jasgit Sachdev

Cancer Discov· June 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I study of MRX34, a liposomal miR-34a mimic, administered twice weekly in patients with advanced solid tumors.
Muhammad S Beg, Andrew J Brenner, Jasgit Sachdev, Mitesh Borad, Yoon-Koo Kang

Invest New Drugs· April 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
AKT in cancer: new molecular insights and advances in drug development.
Prabhjot S Mundi, Jasgit Sachdev, Carolyn McCourt, Kevin Kalinsky

Br J Clin Pharmacol· October 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis